Dr. Maus is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
Massachusetts General Hospital
55 Fruit Street
Boston, MA 02114
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
- University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2008
- Perelman School of Medicine at the University of PennsylvaniaClass of 2005
Certifications & Licensure
- MA State Medical License 2015 - 2026
- PA State Medical License 2006 - 2016
- NY State Medical License 2008 - 2013
Publications & Presentations
PubMed
- CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.Harrison J Silva, Grace Martin, Filippo Birocchi, Marc Wehrli, Michael C Kann
Blood. 2025-02-13 - Single-cell dynamics of breakthrough toxicities following anakinra prophylaxis for axicabtagene ciloleucel in lymphoma.Matthew J Frigault, Estelle Yao, Trisha R Berger, Marc Wehrli, Kathleen M E Gallagher
Blood Advances. 2025-02-10 - 1 citationsAssociation of CD19-targeted chimeric antigen receptor (CAR) T-cell therapy with hypogammaglobulinemia, infection, and mortality.Natalia M Sutherland, Baijun Zhou, Lingxiao Zhang, Mei-Sing Ong, Joseph S Hong
The Journal of Allergy and Clinical Immunology. 2025-02-01
Journal Articles
- Making CAR T Cells a Solid Option for Solid TumorsMarcela Maus, MD, Frontiers in Neurology
- Immunotherapy for Glioblastoma: Adoptive T-cell StrategiesMarcela V Maus, Carl H June, Clinical Cancer Research
Abstracts/Posters
- Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen ReceptorsMarcela V Maus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)Marcela V. Maus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Overcoming a Critical Obstacle Towards Effective and Safe CAR T-Cell Therapeutics2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood CancersSeptember 4th, 2024
- Damon Runyon Cancer Research Foundation Awards $4.8 Million to Exceptional Early-Career ScientistsAugust 28th, 2024
- The Race to Supercharge Cancer-Fighting T CellsJanuary 25th, 2023
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: